Regeneron posts Q3 2026 earnings beat with 36% revenue jump and $1 billion Sanofi upfront payment

Regeneron Pharmaceuticals reported third‑quarter 2026 revenue of $5.12 billion, up 36% year‑over‑year, and non‑GAAP earnings per share of $20.07, a 70% increase. The results were driven by record sales of Dupixent, EYLEA HD and Libtayo, and an expanded Sanofi collaboration that delivered a $1 billion upfront payment with up to $7 billion in future milestones. The company raised its full‑year guidance, including a non‑GAAP gross‑margin target of about 86% and higher R&D and capital‑expenditure forecasts.

The earnings beat and higher guidance suggest stronger cash flow and profitability for the coming year, which could support a higher valuation for REGN (the company expects a robust 2026 performance). The $1 billion upfront payment improves near‑term liquidity and underscores the value of the Sanofi partnership, benefiting both REGN and SNY.

  • 1Q3 2026 revenue was $5.12 billion, up 36% YoY.
  • 2Non‑GAAP EPS was $20.07, up 70% YoY.
  • 3Sanofi paid $1.0 billion upfront for an expanded collaboration, with potential $7.0 billion in future milestones.
  • 4Full‑year 2026 non‑GAAP gross‑margin guidance was raised to about 86%.
  • 5Full‑year 2026 R&D spending forecast was increased to $6.60 billion‑$6.74 billion.
  • 6Full‑year 2026 capital‑expenditure guidance was set at $1.05 billion‑$1.10 billion.

Sources